The CRIMSON project aims to revolutionise the study of the cellular origin of diseases
A breakthrough in microscopy and endoscopy will soon revolutionise the study of the cellular origin of diseases, advancing the field of precision medicine. This is the goal of CRIMSON, a trans-disciplinary and trans-national research project recently funded by European Commission. It will develop the next-generation bio-photonics imaging device for biomedical research, combining advanced laser techniques with artificial-intelligence data analysis. This groundbreaking microscope will provide three-dimensional quantitative maps of sub-cellular compartments in living cells and organoids and enable fast tissue classification with unprecedented biomolecular sensitivity. High acquisition speed will allow the observation of intra and inter-cellular dynamic changes by time-lapse imaging.
The CRIMSON project, starting 1 December 2020, lasting 42 months and with a budget exceeding 5M€, will also simulate future in-vivo studies and demonstrate the capability to image inside the body, realizing an innovative endoscope and applying it to ex-vivo thick tissue samples. The results have potentially profound societal impacts, improving patients’ quality of life and reducing public healthcare costs.
A multidisciplinary team of world-leading organisations with vertical integration of all required skills composes the consortium, coordinated by Politecnico di Milano (Italy). Three research centres (Politecnico di Milano – Italy, Leibniz Institute of Photonic Technology – Germany and Centre National de la Recherche Scientifique – France), with long-standing expertise in photonics, spectroscopy and nonlinear microscopy, will develop the technology. Three biomedical partners (Istituto Nazionale Tumori – Italy, Institut National de la Santé et de la Recherche Médicale – France and Jena University Hospital – Germany) will validate the imaging system on open biological questions related to cancer, as paradigmatic examples of the complexity and heterogeneity of cellular diseases.
Four innovative SMEs (Active Fibre Systems – Germany, Lightcore Technologies – France, Cambridge Raman Imaging- UK and 3rdPlace – Italy), including a biomedical equipment manufacturer, will commercially exploit the innovation, thus creating a competitive advantage in the European biophotonics-related market for microscopes and R&D tools.
